<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Laboratory Diagnosis of STIs - Presentation</title>
		<style>
    * {
        margin: 0;
        padding: 0;
        box-sizing: border-box;
    }
    
    body {
        font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;
        background: #1a202c;
        color: #000;
        overflow: hidden;
    }
    
    .presentation-container {
        height: 100vh;
        display: flex;
        flex-direction: column;
        position: relative;
    }
    
    .slide {
        display: none;
        position: absolute;
        top: 0;
        left: 0;
        width: 100%;
        height: 100%;
        background: white;
        padding: 60px;
        overflow-y: auto;
        animation: fadeIn 0.5s ease-in-out;
    }
    
    .slide.active {
        display: block;
    }
    
    @keyframes fadeIn {
        from { opacity: 0; transform: translateX(20px); }
        to { opacity: 1; transform: translateX(0); }
    }
    
    .slide-header {
        border-bottom: 3px solid #2563eb;
        padding-bottom: 20px;
        margin-bottom: 40px;
    }
    
    .slide-number {
        color: #64748b;
        font-size: 14px;
        margin-bottom: 10px;
    }
    
    h1 {
        color: #1e293b;
        font-size: 42px;
        font-weight: 700;
        line-height: 1.2;
        margin-bottom: 20px;
    }
    
    h2 {
        color: #334155;
        font-size: 32px;
        font-weight: 600;
        margin-bottom: 30px;
    }
    
    h3 {
        color: #475569;
        font-size: 24px;
        font-weight: 600;
        margin-bottom: 20px;
        margin-top: 30px;
    }
    
    .subtitle {
        color: #64748b;
        font-size: 20px;
        margin-bottom: 10px;
    }
    
    .content {
        font-size: 23px;
        line-height: 1.8;
        color: #475569;
        padding-bottom: 100px; /* Add padding to ensure content doesn't hide behind navigation */
    }
    
    ul, ol {
        margin-left: 30px;
        margin-bottom: 20px;
    }
    
    li {
        margin-bottom: 12px;
    }
    
    .highlight {
        background: #fef3c7;
        padding: 2px 8px;
        border-radius: 4px;
        font-weight: 600;
    }
    
    .important {
        color: #dc2626;
        font-weight: 600;
    }
    
    .two-column {
        display: grid;
        grid-template-columns: 1fr 1fr;
        gap: 40px;
        margin-top: 30px;
    }
    
    .info-box {
        background: #f0f9ff;
        border-left: 4px solid #3b82f6;
        padding: 20px;
        margin: 20px 0;
        border-radius: 8px;
    }
    
    .warning-box {
        background: #fef3c7;
        border-left: 4px solid #f59e0b;
        padding: 20px;
        margin: 20px 0;
        border-radius: 8px;
    }
    
    .success-box {
        background: #f0fdf4;
        border-left: 4px solid #22c55e;
        padding: 20px;
        margin: 20px 0;
        border-radius: 8px;
    }
    
    table {
        width: 100%;
        border-collapse: collapse;
        margin: 20px 0;
        font-size: 21px;
    }
    
    th {
        background: #e0e7ff;
        color: #312e81;
        padding: 12px;
        text-align: left;
        font-weight: 600;
    }
    
    td {
        padding: 12px;
        border-bottom: 1px solid #e5e7eb;
    }
    
    tr:hover {
        background: #f9fafb;
    }
    
    .navigation {
        position: fixed;
        bottom: 0;
        left: 0;
        right: 0;
        background: #1e293b;
        padding: 20px;
        display: flex;
        justify-content: space-between;
        align-items: center;
        box-shadow: 0 -4px 6px rgba(0,0,0,0.1);
        z-index: 1000;
    }
    
    .nav-button {
        background: #3b82f6;
        color: white;
        border: none;
        padding: 10px 30px;
        font-size: 16px;
        border-radius: 8px;
        cursor: pointer;
        transition: all 0.2s;
    }
    
    .nav-button:hover {
        background: #2563eb;
        transform: translateY(-2px);
    }
    
    .nav-button:disabled {
        background: #64748b;
        cursor: not-allowed;
        transform: none;
    }
    
    .slide-indicator {
        color: white;
        font-size: 16px;
    }
    
    .progress-bar {
        position: fixed;
        top: 0;
        left: 0;
        height: 4px;
        background: #3b82f6;
        transition: width 0.3s ease;
        z-index: 1001;
    }
    
    .image-placeholder {
        background: #e5e7eb;
        border: 2px dashed #9ca3af;
        padding: 40px;
        text-align: center;
        color: #6b7280;
        border-radius: 8px;
        margin: 20px 0;
    }
    
    .algorithm-box {
        background: #fafafa;
        border: 2px solid #e5e7eb;
        border-radius: 12px;
        padding: 30px;
        margin: 20px 0;
    }
    
    .test-comparison {
        display: grid;
        grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
        gap: 20px;
        margin: 20px 0;
    }
    
    .test-card {
        background: #f8fafc;
        border: 1px solid #e2e8f0;
        border-radius: 12px;
        padding: 20px;
        transition: all 0.2s;
    }
    
    .test-card:hover {
        transform: translateY(-4px);
        box-shadow: 0 4px 12px rgba(0,0,0,0.1);
    }
    
    .test-card h4 {
        color: #1e293b;
        margin-bottom: 10px;
    }
    
    .test-sensitivity {
        background: #dcfce7;
        color: #166534;
        padding: 4px 8px;
        border-radius: 4px;
        font-size: 14px;
        display: inline-block;
        margin-top: 10px;
    }
    
    .test-specificity {
        background: #dbeafe;
        color: #1e3a8a;
        padding: 4px 8px;
        border-radius: 4px;
        font-size: 14px;
        display: inline-block;
        margin-top: 10px;
    }

    .title-slide {
        display: flex;
        flex-direction: column;
        justify-content: center;
        align-items: center;
        text-align: center;
        background: linear-gradient(135deg, #1e3a8a 0%, #312e81 100%);
        color: white;
        padding: 60px;
    }
    
    .title-slide h1 {
        color: white;
        font-size: 56px;
        margin-bottom: 30px;
    }
    
    .title-slide .subtitle {
        color: #e0e7ff;
        font-size: 27px;
    }
    
    .presenter-info {
        margin-top: 60px;
        font-size: 20px;
        color: #e0e7ff;
    }
    
    @media (max-width: 768px) {
        .slide {
            padding: 40px 20px;
        }
        
        h1 {
            font-size: 32px;
        }
        
        h2 {
            font-size: 24px;
        }
        
        .two-column {
            grid-template-columns: 1fr;
        }
        
        .content {
            padding-bottom: 120px;
        }
    }
	</style>
</head>
<body>
    <div class="presentation-container">
        <div class="progress-bar" id="progressBar"></div>
        
        <!-- Slide 1: Title Slide -->
        <div class="slide active title-slide">
            <h1>Laboratory Diagnosis of Sexually Transmitted Infections</h1>
            <p class="subtitle">التشخيص المخبري للأمراض المنقولة جنسياً</p>
            <div class="presenter-info">
                <p>Ministry of Health - Saudi Arabia</p>
                <p>STI Control Program</p>
                <p id="currentDate"></p>
            </div>
        </div>
        
        <!-- Slide 2: Introduction -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 2 of 45</p>
                <h1>Introduction and Importance</h1>
            </div>
            <div class="content">
                <h3>Why Accurate Laboratory Diagnosis Matters</h3>
                <ul>
                    <li>STIs are a major public health concern globally and in Saudi Arabia</li>
                    <li>Many STIs are <span class="highlight">asymptomatic</span> - laboratory testing is crucial</li>
                    <li>Accurate diagnosis enables:
                        <ul>
                            <li>Appropriate treatment selection</li>
                            <li>Prevention of complications</li>
                            <li>Partner notification and treatment</li>
                            <li>Surveillance and public health planning</li>
                        </ul>
                    </li>
                </ul>
                
                <div class="info-box">
                    <strong>Key Point:</strong> Laboratory diagnosis is the cornerstone of STI control programs
                </div>
                
                <h3>Lecture Overview</h3>
                <ol>
                    <li>General principles and quality standards</li>
                    <li>Pathogen-specific diagnostic approaches</li>
                    <li>Modern technologies and future directions</li>
                    <li>Practical implementation guidelines</li>
                </ol>
            </div>
        </div>
        
        <!-- Slide 3: General Principles -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 3 of 45</p>
                <h1>General Principles in STI Laboratory Diagnosis</h1>
            </div>
            <div class="content">
                <h3>Types of Diagnostic Tests</h3>
                <div class="test-comparison">
                    <div class="test-card">
                        <h4>Direct Detection</h4>
                        <ul>
                            <li>Microscopy</li>
                            <li>Antigen detection</li>
                            <li>Nucleic acid tests</li>
                        </ul>
                        <span class="test-sensitivity">High specificity</span>
                    </div>
                    <div class="test-card">
                        <h4>Culture Methods</h4>
                        <ul>
                            <li>Bacterial culture</li>
                            <li>Viral culture</li>
                            <li>Susceptibility testing</li>
                        </ul>
                        <span class="test-specificity">100% specificity</span>
                    </div>
                    <div class="test-card">
                        <h4>Serological Tests</h4>
                        <ul>
                            <li>Antibody detection</li>
                            <li>Antigen detection</li>
                            <li>Screening & confirmation</li>
                        </ul>
                        <span class="test-sensitivity">Variable sensitivity</span>
                    </div>
                </div>
            </div>
        </div>
        
        <!-- Slide 4: Specimen Collection -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 4 of 45</p>
                <h1>Specimen Collection and Handling</h1>
            </div>
            <div class="content">
                <h3>Critical Pre-analytical Factors</h3>
                
                <div class="two-column">
                    <div>
                        <h4>Specimen Types</h4>
                        <ul>
                            <li><strong>Urogenital:</strong> Urine, urethral, cervical, vaginal swabs</li>
                            <li><strong>Extragenital:</strong> Pharyngeal, rectal swabs</li>
                            <li><strong>Blood:</strong> Serum, plasma, whole blood</li>
                            <li><strong>Lesions:</strong> Ulcer swabs, vesicle fluid</li>
                        </ul>
                    </div>
                    <div>
                        <h4>Collection Timing</h4>
                        <ul>
                            <li>Window periods for antibody tests</li>
                            <li>First-void urine for NAAT</li>
                            <li>Active lesions for direct detection</li>
                            <li>Avoid recent urination (≥1 hour)</li>
                        </ul>
                    </div>
                </div>
                
                <div class="warning-box">
                    <strong>Important:</strong> Improper specimen collection is the most common cause of false-negative results
                </div>
                
                <h3>Transport and Storage</h3>
                <table>
                    <tr>
                        <th>Specimen Type</th>
                        <th>Transport Medium</th>
                        <th>Temperature</th>
                        <th>Maximum Time</th>
                    </tr>
                    <tr>
                        <td>NAAT swabs</td>
                        <td>Manufacturer's medium</td>
                        <td>2-8°C</td>
                        <td>7 days</td>
                    </tr>
                    <tr>
                        <td>Culture swabs</td>
                        <td>Stuart's/Amies</td>
                        <td>Room temp</td>
                        <td>24 hours</td>
                    </tr>
                    <tr>
                        <td>Serum</td>
                        <td>None</td>
                        <td>2-8°C</td>
                        <td>7 days</td>
                    </tr>
                </table>
            </div>
        </div>
        
        <!-- Slide 5: Quality Standards -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 5 of 45</p>
                <h1>Laboratory Quality Standards</h1>
            </div>
            <div class="content">
                <h3>Essential Quality Elements</h3>
                
                <div class="algorithm-box">
                    <h4>Quality Management System</h4>
                    <ol>
                        <li><strong>Pre-analytical:</strong> Proper specimen collection, labeling, transport</li>
                        <li><strong>Analytical:</strong> Test performance, controls, calibration</li>
                        <li><strong>Post-analytical:</strong> Result interpretation, reporting, archiving</li>
                    </ol>
                </div>
                
                <div class="two-column">
                    <div>
                        <h4>Internal Quality Control</h4>
                        <ul>
                            <li>Daily positive/negative controls</li>
                            <li>Equipment calibration</li>
                            <li>Staff competency assessment</li>
                            <li>SOPs and documentation</li>
                        </ul>
                    </div>
                    <div>
                        <h4>External Quality Assessment</h4>
                        <ul>
                            <li>Proficiency testing programs</li>
                            <li>Inter-laboratory comparisons</li>
                            <li>Accreditation requirements</li>
                            <li>Continuous improvement</li>
                        </ul>
                    </div>
                </div>
                
                <div class="success-box">
                    <strong>Best Practice:</strong> Participate in international EQA programs for STI testing
                </div>
            </div>
        </div>
        
        <!-- Slide 6: Common Challenges -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 6 of 45</p>
                <h1>Common Diagnostic Challenges</h1>
            </div>
            <div class="content">
                <h3>Technical Challenges</h3>
                <ul>
                    <li><strong>Cross-reactivity:</strong> False positives in serological tests</li>
                    <li><strong>Sensitivity issues:</strong> Early infection, low pathogen load</li>
                    <li><strong>Specimen adequacy:</strong> Insufficient cells/material</li>
                    <li><strong>Inhibitors:</strong> Substances affecting molecular tests</li>
                </ul>
                
                <h3>Clinical Challenges</h3>
                <div class="two-column">
                    <div>
                        <h4>Patient Factors</h4>
                        <ul>
                            <li>Recent antibiotic use</li>
                            <li>Immunosuppression</li>
                            <li>Co-infections</li>
                            <li>Anatomical variations</li>
                        </ul>
                    </div>
                    <div>
                        <h4>Testing Limitations</h4>
                        <ul>
                            <li>Window periods</li>
                            <li>Test availability</li>
                            <li>Cost constraints</li>
                            <li>Turnaround time</li>
                        </ul>
                    </div>
                </div>
                
                <div class="info-box">
                    <strong>Solution:</strong> Use appropriate testing algorithms and confirmatory tests when indicated
                </div>
            </div>
        </div>
        
        <!-- Slide 7: Syphilis Introduction -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 7 of 45</p>
                <h1>Syphilis (Treponema pallidum) Diagnosis</h1>
            </div>
            <div class="content">
                <h3>Overview</h3>
                <ul>
                    <li>Causative agent: <em>Treponema pallidum</em> subspecies <em>pallidum</em></li>
                    <li>Cannot be cultured in routine laboratory</li>
                    <li>Diagnosis relies on direct detection and serology</li>
                    <li>Different tests needed for different stages</li>
                </ul>
                
                <h3>Clinical Stages and Testing</h3>
                <table>
                    <tr>
                        <th>Stage</th>
                        <th>Clinical Features</th>
                        <th>Preferred Tests</th>
                    </tr>
                    <tr>
                        <td>Primary</td>
                        <td>Chancre (3-90 days)</td>
                        <td>Direct detection + Serology</td>
                    </tr>
                    <tr>
                        <td>Secondary</td>
                        <td>Rash, systemic symptoms</td>
                        <td>Serology (high titers)</td>
                    </tr>
                    <tr>
                        <td>Latent</td>
                        <td>Asymptomatic</td>
                        <td>Serology only</td>
                    </tr>
                    <tr>
                        <td>Tertiary</td>
                        <td>Gummas, cardiovascular, neuro</td>
                        <td>Serology + CSF (if neuro)</td>
                    </tr>
                </table>
            </div>
        </div>
        
        <!-- Slide 8: Syphilis Direct Detection -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 8 of 45</p>
                <h1>Syphilis: Direct Detection Methods</h1>
            </div>
            <div class="content">
                <h3>Direct Detection Techniques</h3>
                
                <div class="test-comparison">
                    <div class="test-card">
                        <h4>Darkfield Microscopy</h4>
                        <ul>
                            <li>Requires fresh specimen</li>
                            <li>Experienced microscopist</li>
                            <li>See spirochetes moving</li>
                        </ul>
                        <span class="test-sensitivity">Sensitivity: 80%</span>
                        <span class="test-specificity">Specificity: 97%</span>
                    </div>
                    <div class="test-card">
                        <h4>DFA-TP</h4>
                        <ul>
                            <li>Fluorescent antibody stain</li>
                            <li>Can use fixed specimens</li>
                            <li>More specific than darkfield</li>
                        </ul>
                        <span class="test-sensitivity">Sensitivity: 90%</span>
                        <span class="test-specificity">Specificity: 99%</span>
                    </div>
                    <div class="test-card">
                        <h4>PCR</h4>
                        <ul>
                            <li>Most sensitive method</li>
                            <li>Not widely available</li>
                            <li>Research settings</li>
                        </ul>
                        <span class="test-sensitivity">Sensitivity: 95%</span>
                        <span class="test-specificity">Specificity: 99%</span>
                    </div>
                </div>
                
                <div class="warning-box">
                    <strong>Note:</strong> Direct detection is only useful when lesions are present (primary & secondary syphilis)
                </div>
            </div>
        </div>
        
        <!-- Slide 9: Syphilis Serology -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 9 of 45</p>
                <h1>Syphilis: Serological Tests</h1>
            </div>
            <div class="content">
                <h3>Two Categories of Serological Tests</h3>
                
                <div class="two-column">
                    <div>
                        <h4>Non-treponemal Tests</h4>
                        <ul>
                            <li><strong>RPR</strong> (Rapid Plasma Reagin)</li>
                            <li><strong>VDRL</strong> (Venereal Disease Research Lab)</li>
                            <li>Detect antibodies to cardiolipin</li>
                            <li>Quantitative (titer)</li>
                            <li>Monitor treatment response</li>
                        </ul>
                        <div class="warning-box" style="margin-top: 20px;">
                            <strong>False Positives:</strong> Pregnancy, autoimmune diseases, elderly
                        </div>
                    </div>
                    <div>
                        <h4>Treponemal Tests</h4>
                        <ul>
                            <li><strong>TPPA/TPHA</strong></li>
                            <li><strong>FTA-ABS</strong></li>
                            <li><strong>EIA/CIA</strong></li>
                            <li><strong>Immunoblots</strong></li>
                            <li>Remain positive for life</li>
                            <li>Confirmatory tests</li>
                        </ul>
                        <div class="success-box" style="margin-top: 20px;">
                            <strong>Advantage:</strong> More specific for T. pallidum
                        </div>
                    </div>
                </div>
            </div>
        </div>
        
        <!-- Slide 10: Syphilis Testing Algorithms -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 10 of 45</p>
                <h1>Syphilis Testing Algorithms</h1>
            </div>
            <div class="content">
                <h3>Traditional vs Reverse Algorithm</h3>
                
                <div class="two-column">
                    <div>
                        <h4>Traditional Algorithm</h4>
                        <div class="algorithm-box">
                            <ol>
                                <li>Screen with RPR/VDRL</li>
                                <li>If positive → Confirm with TPPA</li>
                                <li>Report with titer</li>
                            </ol>
                            <p style="margin-top: 15px;"><strong>Pros:</strong> Cost-effective, monitors treatment</p>
                            <p><strong>Cons:</strong> May miss early/late syphilis</p>
                        </div>
                    </div>
                    <div>
                        <h4>Reverse Algorithm</h4>
                        <div class="algorithm-box">
                            <ol>
                                <li>Screen with EIA/CIA</li>
                                <li>If positive → RPR/VDRL</li>
                                <li>Discordant → TPPA</li>
                            </ol>
                            <p style="margin-top: 15px;"><strong>Pros:</strong> Higher sensitivity, automation</p>
                            <p><strong>Cons:</strong> More complex interpretation</p>
                        </div>
                    </div>
                </div>
                
                <h3>Result Interpretation</h3>
                <table>
                    <tr>
                        <th>Treponemal</th>
                        <th>Non-treponemal</th>
                        <th>Interpretation</th>
                    </tr>
                    <tr>
                        <td>Positive</td>
                        <td>Positive</td>
                        <td>Active syphilis (confirm stage)</td>
                    </tr>
                    <tr>
                        <td>Positive</td>
                        <td>Negative</td>
                        <td>Past treated syphilis OR early/late syphilis</td>
                    </tr>
                    <tr>
                        <td>Negative</td>
                        <td>Positive</td>
                        <td>False positive (confirm with another treponemal)</td>
                    </tr>
                </table>
            </div>
        </div>
        
        <!-- Slide 11: Syphilis Treatment Monitoring -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 11 of 45</p>
                <h1>Syphilis: Treatment Monitoring</h1>
            </div>
            <div class="content">
                <h3>Monitoring Treatment Response</h3>
                
                <div class="info-box">
                    <strong>Key Principle:</strong> Use quantitative non-treponemal tests (RPR/VDRL) to monitor treatment
                </div>
                
                <h4>Expected Response</h4>
                <ul>
                    <li>4-fold decline in titer = successful treatment</li>
                    <li>Check at 6 and 12 months for primary/secondary</li>
                    <li>Check at 6, 12, and 24 months for latent</li>
                </ul>
                
                <h4>Treatment Failure Indicators</h4>
                <ul>
                    <li>Lack of 4-fold decline by 6-12 months</li>
                    <li>4-fold increase in titer</li>
                    <li>Clinical signs persist/recur</li>
                </ul>
                
                <div class="warning-box">
                    <strong>Remember:</strong> Treponemal tests remain positive for life - do NOT use for monitoring
                </div>
            </div>
        </div>
        
        <!-- Slide 12: Gonorrhea Introduction -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 12 of 45</p>
                <h1>Gonorrhea (Neisseria gonorrhoeae) Diagnosis</h1>
            </div>
            <div class="content">
                <h3>Overview</h3>
                <ul>
                    <li>Gram-negative intracellular diplococcus</li>
                    <li>Affects urogenital, pharyngeal, and rectal sites</li>
                    <li>Often asymptomatic, especially in women</li>
                    <li><span class="important">Rising antimicrobial resistance - major concern</span></li>
                </ul>
                
                <h3>Diagnostic Methods Overview</h3>
                <div class="test-comparison">
                    <div class="test-card">
                        <h4>Microscopy</h4>
                        <p>Gram stain</p>
                        <p>Rapid results</p>
                        <p>Male urethral only</p>
                    </div>
                    <div class="test-card">
                        <h4>Culture</h4>
                        <p>Gold standard</p>
                        <p>Susceptibility testing</p>
                        <p>All sites</p>
                    </div>
                    <div class="test-card">
                        <h4>NAAT</h4>
                        <p>Most sensitive</p>
                        <p>Non-viable organisms</p>
                        <p>Multiple sites</p>
                    </div>
                </div>
            </div>
        </div>
        
        <!-- Slide 13: Gonorrhea Microscopy and Culture -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 13 of 45</p>
                <h1>Gonorrhea: Microscopy and Culture</h1>
            </div>
            <div class="content">
                <h3>Gram Stain Microscopy</h3>
                <div class="two-column">
                    <div>
                        <h4>Procedure</h4>
                        <ul>
                            <li>Direct smear from discharge</li>
                            <li>Gram stain technique</li>
                            <li>Look for intracellular diplococci</li>
                            <li>Inside polymorphonuclear cells</li>
                        </ul>
                    </div>
                    <div>
                        <h4>Performance by Site</h4>
                        <ul>
                            <li><strong>Male urethra:</strong> Sens 95%, Spec 99%</li>
                            <li><strong>Cervix:</strong> Sens 50%, Spec 95%</li>
                            <li><strong>Pharynx/Rectum:</strong> Not recommended</li>
                        </ul>
                    </div>
                </div>
                
                <h3>Culture Methods</h3>
                <div class="algorithm-box">
                    <h4>Culture Requirements</h4>
                    <ul>
                        <li><strong>Media:</strong> Chocolate agar, Thayer-Martin (selective)</li>
                        <li><strong>Atmosphere:</strong> 5-10% CO₂, 35-37°C</li>
                        <li><strong>Transport:</strong> Immediate plating or transport medium</li>
                        <li><strong>Identification:</strong> Oxidase, catalase, sugar utilization</li>
                    </ul>
                </div>
                
                <div class="success-box">
                    <strong>Critical:</strong> Culture enables antimicrobial susceptibility testing - essential for resistance surveillance
                </div>
            </div>
        </div>
        
        <!-- Slide 14: Gonorrhea NAAT -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 14 of 45</p>
                <h1>Gonorrhea: Nucleic Acid Testing</h1>
            </div>
            <div class="content">
                <h3>NAAT Advantages</h3>
                <ul>
                    <li>Superior sensitivity (>95%) compared to culture</li>
                    <li>Can test multiple anatomical sites</li>
                    <li>Stable specimens - no viability required</li>
                    <li>Automated platforms available</li>
                    <li>Co-testing with Chlamydia</li>
                </ul>
                
                <h3>Specimen Types for NAAT</h3>
                <table>
                    <tr>
                        <th>Patient</th>
                        <th>Specimen</th>
                        <th>Collection</th>
                        <th>Notes</th>
                    </tr>
                    <tr>
                        <td>Males</td>
                        <td>First-void urine</td>
                        <td>First 10-20 mL</td>
                        <td>No urination ≥1 hour</td>
                    </tr>
                    <tr>
                        <td>Females</td>
                        <td>Vaginal swab</td>
                        <td>Self or clinician</td>
                        <td>Preferred specimen</td>
                    </tr>
                    <tr>
                        <td>All</td>
                        <td>Pharyngeal</td>
                        <td>Posterior pharynx</td>
                        <td>Based on exposure</td>
                    </tr>
                    <tr>
                        <td>All</td>
                        <td>Rectal</td>
                        <td>Anal canal</td>
                        <td>Based on exposure</td>
                    </tr>
                </table>
                
                <div class="warning-box">
                    <strong>Limitation:</strong> NAAT cannot provide antimicrobial susceptibility - culture still needed for resistance testing
                </div>
            </div>
        </div>
        
        <!-- Slide 15: Gonorrhea Resistance -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 15 of 45</p>
                <h1>Gonorrhea: Antimicrobial Resistance Testing</h1>
            </div>
            <div class="content">
                <h3>Global Resistance Crisis</h3>
                <ul>
                    <li>Resistance to all first-line antibiotics has emerged</li>
                    <li>Ceftriaxone is last remaining empiric option</li>
                    <li>XDR (extensively drug-resistant) strains reported</li>
                </ul>
                
                <h3>Susceptibility Testing Methods</h3>
                <div class="two-column">
                    <div>
                        <h4>Disk Diffusion</h4>
                        <ul>
                            <li>Standardized method</li>
                            <li>CLSI guidelines</li>
                            <li>Qualitative results</li>
                        </ul>
                    </div>
                    <div>
                        <h4>MIC Testing</h4>
                        <ul>
                            <li>E-test or agar dilution</li>
                            <li>Quantitative results</li>
                            <li>Required for surveillance</li>
                        </ul>
                    </div>
                </div>
                
                <div class="info-box">
                    <strong>Saudi Recommendation:</strong> Culture from treatment failures and perform susceptibility testing
                </div>
            </div>
        </div>
        
        <!-- Slide 16: Chlamydia Introduction -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 16 of 45</p>
                <h1>Chlamydia trachomatis Diagnosis</h1>
            </div>
            <div class="content">
                <h3>Overview</h3>
                <ul>
                    <li>Obligate intracellular bacterium</li>
                    <li>Most common bacterial STI worldwide</li>
                    <li>70-80% asymptomatic in women</li>
                    <li>Major cause of PID and infertility</li>
                    <li>Includes LGV serovars (L1, L2, L3)</li>
                </ul>
                
                <h3>Diagnostic Evolution</h3>
                <div class="algorithm-box">
                    <p><strong>Historical:</strong> Cell culture (McCoy cells) → Complex, expensive</p>
                    <p><strong>Transitional:</strong> Direct fluorescent antibody, EIA → Lower sensitivity</p>
                    <p><strong>Current Standard:</strong> NAAT → Highly sensitive and specific</p>
                </div>
                
                <div class="success-box">
                    <strong>Key Point:</strong> NAAT is the only recommended method for routine chlamydia diagnosis
                </div>
            </div>
        </div>
        
        <!-- Slide 17: Chlamydia NAAT Testing -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 17 of 45</p>
                <h1>Chlamydia: NAAT Testing</h1>
            </div>
            <div class="content">
                <h3>NAAT Performance</h3>
                <ul>
                    <li>Sensitivity: >90-95%</li>
                    <li>Specificity: >99%</li>
                    <li>FDA-approved for multiple specimen types</li>
                    <li>Can detect as few as 1-10 organisms</li>
                </ul>
                
                <h3>Specimen Selection</h3>
                <table>
                    <tr>
                        <th>Clinical Scenario</th>
                        <th>Preferred Specimen</th>
                        <th>Alternative</th>
                    </tr>
                    <tr>
                        <td>Asymptomatic female screening</td>
                        <td>Vaginal swab (self-collected)</td>
                        <td>First-void urine</td>
                    </tr>
                    <tr>
                        <td>Symptomatic female</td>
                        <td>Cervical swab</td>
                        <td>Vaginal swab</td>
                    </tr>
                    <tr>
                        <td>Male (any)</td>
                        <td>First-void urine</td>
                        <td>Urethral swab</td>
                    </tr>
                    <tr>
                        <td>Extragenital</td>
                        <td>Site-specific swab</td>
                        <td>-</td>
                    </tr>
                </table>
                
                <h3>Co-testing Advantages</h3>
                <ul>
                    <li>Most platforms test for C. trachomatis + N. gonorrhoeae</li>
                    <li>Single specimen, reduced cost</li>
                    <li>High co-infection rates justify dual testing</li>
                </ul>
            </div>
        </div>
        
        <!-- Slide 18: Chlamydia Special Considerations -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 18 of 45</p>
                <h1>Chlamydia: Special Considerations</h1>
            </div>
            <div class="content">
                <h3>LGV (Lymphogranuloma Venereum) Testing</h3>
                <div class="info-box">
                    <ul>
                        <li>Caused by C. trachomatis serovars L1, L2, L3</li>
                        <li>Requires genotyping - not available in routine labs</li>
                        <li>Clinical diagnosis + positive chlamydia NAAT</li>
                        <li>Consider in: proctitis, inguinal buboes, genital ulcers</li>
                    </ul>
                </div>
                
                <h3>Test of Cure</h3>
                <ul>
                    <li>NOT recommended routinely due to dead organism detection</li>
                    <li>Wait ≥4 weeks if testing needed</li>
                    <li>Indicated for:
                        <ul>
                            <li>Pregnant women</li>
                            <li>Compliance concerns</li>
                            <li>Persistent symptoms</li>
                        </ul>
                    </li>
                </ul>
                
                <h3>False Results</h3>
                <div class="two-column">
                    <div>
                        <h4>False Positives</h4>
                        <ul>
                            <li>Very rare with NAAT</li>
                            <li>Low prevalence populations</li>
                            <li>Consider confirmatory testing</li>
                        </ul>
                    </div>
                    <div>
                        <h4>False Negatives</h4>
                        <ul>
                            <li>Recent exposure (<7 days)</li>
                            <li>Inhibitors in specimen</li>
                            <li>Improper collection</li>
                        </ul>
                    </div>
                </div>
            </div>
        </div>
        
        <!-- Slide 19: Trichomoniasis Introduction -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 19 of 45</p>
                <h1>Trichomoniasis Diagnosis</h1>
            </div>
            <div class="content">
                <h3>Overview</h3>
                <ul>
                    <li>Causative agent: <em>Trichomonas vaginalis</em> (protozoan)</li>
                    <li>Most common non-viral STI globally</li>
                    <li>Associated with adverse pregnancy outcomes</li>
                    <li>Increases HIV transmission risk</li>
                    <li>Often asymptomatic (70-85%)</li>
                </ul>
                
                <h3>Diagnostic Methods Comparison</h3>
                <table>
                    <tr>
                        <th>Method</th>
                        <th>Sensitivity</th>
                        <th>Advantages</th>
                        <th>Limitations</th>
                    </tr>
                    <tr>
                        <td>Wet Mount</td>
                        <td>44-68%</td>
                        <td>Rapid, inexpensive</td>
                        <td>Requires immediate exam</td>
                    </tr>
                    <tr>
                        <td>Culture</td>
                        <td>75-96%</td>
                        <td>Viable organisms</td>
                        <td>3-7 days, special media</td>
                    </tr>
                    <tr>
                        <td>NAAT</td>
                        <td>>95%</td>
                        <td>Highly sensitive</td>
                        <td>Cost, availability</td>
                    </tr>
                    <tr>
                        <td>Rapid Antigen</td>
                        <td>82-95%</td>
                        <td>Point-of-care</td>
                        <td>Moderate sensitivity</td>
                    </tr>
                </table>
            </div>
        </div>
        
        <!-- Slide 20: Trichomoniasis Testing Methods -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 20 of 45</p>
                <h1>Trichomoniasis: Testing Methods</h1>
            </div>
            <div class="content">
                <h3>Wet Mount Microscopy</h3>
                <div class="algorithm-box">
                    <h4>Procedure</h4>
                    <ol>
                        <li>Mix vaginal discharge with saline</li>
                        <li>Examine immediately (within 10 minutes)</li>
                        <li>Look for motile, flagellated organisms</li>
                        <li>Trichomonads are pear-shaped, 10-20 μm</li>
                    </ol>
                </div>
                
                <div class="warning-box">
                    <strong>Critical:</strong> Sensitivity decreases to 20% after 1 hour - immediate examination essential
                </div>
                
                <h3>Culture Methods</h3>
                <ul>
                    <li><strong>InPouch TV:</strong> Self-contained system, read daily for 5 days</li>
                    <li><strong>Diamond's medium:</strong> Traditional culture method</li>
                    <li>Incubate at 37°C</li>
                    <li>More sensitive than wet mount</li>
                </ul>
                
                <h3>NAAT Testing</h3>
                <div class="success-box">
                    <strong>Preferred Method:</strong> NAAT is recommended for all symptomatic women and high-risk populations
                    <ul style="margin-top: 10px;">
                        <li>Can test vaginal, endocervical, or urine specimens</li>
                        <li>Some assays FDA-approved for male urine</li>
                        <li>Allows for batching and automation</li>
                    </ul>
                </div>
            </div>
        </div>
        
        <!-- Slide 21: HSV Introduction -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 21 of 45</p>
                <h1>Herpes Simplex Virus (HSV) Diagnosis</h1>
            </div>
            <div class="content">
                <h3>Overview</h3>
                <ul>
                    <li>Two types: HSV-1 and HSV-2</li>
                    <li>Both can cause genital and oral infections</li>
                    <li>Lifelong infection with recurrences</li>
                    <li>Can be transmitted during asymptomatic shedding</li>
                    <li>Clinical diagnosis often unreliable</li>
                </ul>
                
                <h3>When to Test</h3>
                <div class="two-column">
                    <div>
                        <h4>Direct Detection (Lesions)</h4>
                        <ul>
                            <li>Active vesicles/ulcers</li>
                            <li>Atypical lesions</li>
                            <li>Confirm clinical diagnosis</li>
                            <li>Type-specific identification</li>
                        </ul>
                    </div>
                    <div>
                        <h4>Serology (No Lesions)</h4>
                        <ul>
                            <li>Recurrent symptoms</li>
                            <li>Partner with HSV</li>
                            <li>HIV-positive patients</li>
                            <li>NOT for screening</li>
                        </ul>
                    </div>
                </div>
            </div>
        </div>
        
        <!-- Slide 22: HSV Direct Detection -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 22 of 45</p>
                <h1>HSV: Direct Detection Methods</h1>
            </div>
            <div class="content">
                <h3>Specimen Collection</h3>
                <ul>
                    <li>Unroof vesicle with needle/scalpel</li>
                    <li>Absorb vesicle fluid with swab</li>
                    <li>Vigorously swab base of ulcer</li>
                    <li>Place in viral transport medium</li>
                </ul>
                
                <h3>Detection Methods</h3>
                <div class="test-comparison">
                    <div class="test-card">
                        <h4>PCR (Preferred)</h4>
                        <ul>
                            <li>Most sensitive method</li>
                            <li>HSV-1 vs HSV-2</li>
                            <li>Quantitative available</li>
                        </ul>
                        <span class="test-sensitivity">Sensitivity: >95%</span>
                    </div>
                    <div class="test-card">
                        <h4>Viral Culture</h4>
                        <ul>
                            <li>100% specific</li>
                            <li>Lower sensitivity</li>
                            <li>Typing possible</li>
                        </ul>
                        <span class="test-sensitivity">Sensitivity: 50-70%</span>
                    </div>
                    <div class="test-card">
                        <h4>DFA</h4>
                        <ul>
                            <li>Rapid results</li>
                            <li>Requires expertise</li>
                            <li>Less sensitive</li>
                        </ul>
                        <span class="test-sensitivity">Sensitivity: 60-70%</span>
                    </div>
                </div>
                
                <div class="info-box">
                    <strong>Timing Matters:</strong> Sensitivity decreases as lesions heal - test early lesions
                </div>
            </div>
        </div>
        
        <!-- Slide 23: HSV Serology -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 23 of 45</p>
                <h1>HSV: Serological Testing</h1>
            </div>
            <div class="content">
                <h3>Type-Specific Serology</h3>
                <ul>
                    <li>Detects IgG antibodies to HSV-1 and HSV-2</li>
                    <li>Based on glycoprotein G (gG-1 and gG-2)</li>
                    <li>Takes 12 weeks to develop antibodies</li>
                    <li>Cannot determine infection site</li>
                </ul>
                
                <h3>Available Tests</h3>
                <table>
                    <tr>
                        <th>Test Type</th>
                        <th>Performance</th>
                        <th>Comments</th>
                    </tr>
                    <tr>
                        <td>HerpeSelect EIA</td>
                        <td>Sens: 96-100%<br>Spec: 96-100%</td>
                        <td>Laboratory-based</td>
                    </tr>
                    <tr>
                        <td>Western Blot</td>
                        <td>Gold standard</td>
                        <td>Research only</td>
                    </tr>
                    <tr>
                        <td>Point-of-care</td>
                        <td>Variable</td>
                        <td>Not recommended</td>
                    </tr>
                </table>
                
                <div class="warning-box">
                    <strong>Caution:</strong> Positive serology does not indicate active infection or infectivity
                </div>
                
                <h3>Interpretation Challenges</h3>
                <ul>
                    <li>False positives in low-risk populations</li>
                    <li>Consider confirmatory testing for low-positive results</li>
                    <li>Cannot distinguish oral from genital infection</li>
                </ul>
            </div>
        </div>
        
        <!-- Slide 24: HPV Introduction -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 24 of 45</p>
                <h1>Human Papillomavirus (HPV) Diagnosis</h1>
            </div>
            <div class="content">
                <h3>Overview</h3>
                <ul>
                    <li>>150 HPV types, ~40 affect genital area</li>
                    <li>High-risk types: 16, 18 (70% of cervical cancers)</li>
                    <li>Low-risk types: 6, 11 (90% of genital warts)</li>
                    <li>Most infections clear spontaneously</li>
                </ul>
                
                <h3>HPV Testing Indications</h3>
                <div class="two-column">
                    <div>
                        <h4>Recommended</h4>
                        <ul>
                            <li>Cervical cancer screening</li>
                            <li>ASC-US triage</li>
                            <li>Post-treatment monitoring</li>
                            <li>Primary screening >30 years</li>
                        </ul>
                    </div>
                    <div>
                        <h4>NOT Recommended</h4>
                        <ul>
                            <li>Men (any site)</li>
                            <li>Genital wart diagnosis</li>
                            <li>Routine STI screening</li>
                            <li>Women <30 years (alone)</li>
                        </ul>
                    </div>
                </div>
                
                <div class="info-box">
                    <strong>Key Point:</strong> HPV testing is for cervical cancer prevention, not STI diagnosis
                </div>
            </div>
        </div>
        
        <!-- Slide 25: HPV Testing Methods -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 25 of 45</p>
                <h1>HPV: Testing Methods</h1>
            </div>
            <div class="content">
                <h3>HPV Detection Technologies</h3>
                
                <div class="test-comparison">
                    <div class="test-card">
                        <h4>Hybrid Capture 2</h4>
                        <ul>
                            <li>Detects 13 HR types</li>
                            <li>DNA probe test</li>
                            <li>Semi-quantitative</li>
                        </ul>
                    </div>
                    <div class="test-card">
                        <h4>Cobas HPV</h4>
                        <ul>
                            <li>PCR-based</li>
                            <li>Types 16, 18 + 12 others</li>
                            <li>FDA-approved primary</li>
                        </ul>
                    </div>
                    <div class="test-card">
                        <h4>Aptima HPV</h4>
                        <ul>
                            <li>mRNA detection</li>
                            <li>14 HR types</li>
                            <li>Higher specificity</li>
                        </ul>
                    </div>
                </div>
                
                <h3>Screening Algorithms</h3>
                <table>
                    <tr>
                        <th>Age Group</th>
                        <th>Recommended Screening</th>
                    </tr>
                    <tr>
                        <td>21-29 years</td>
                        <td>Cytology alone every 3 years</td>
                    </tr>
                    <tr>
                        <td>30-65 years</td>
                        <td>Co-testing (Cytology + HPV) every 5 years<br>OR Cytology alone every 3 years</td>
                    </tr>
                    <tr>
                        <td>>65 years</td>
                        <td>Stop if adequate prior screening</td>
                    </tr>
                </table>
            </div>
        </div>
        
        <!-- Slide 26: Other Pathogens - M. genitalium -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 26 of 45</p>
                <h1>Mycoplasma genitalium Diagnosis</h1>
            </div>
            <div class="content">
                <h3>Clinical Significance</h3>
                <ul>
                    <li>Causes 15-20% of NGU in men</li>
                    <li>Associated with PID in women</li>
                    <li>High rates of antibiotic resistance</li>
                    <li>Often persistent/recurrent</li>
                </ul>
                
                <h3>Diagnostic Approach</h3>
                <div class="algorithm-box">
                    <h4>Testing Indications</h4>
                    <ul>
                        <li>Persistent/recurrent urethritis</li>
                        <li>Persistent/recurrent cervicitis</li>
                        <li>PID evaluation</li>
                        <li>Contact of positive case</li>
                    </ul>
                </div>
                
                <h3>Laboratory Methods</h3>
                <ul>
                    <li><strong>NAAT only</strong> - cannot be cultured routinely</li>
                    <li>FDA-approved assays now available</li>
                    <li>Resistance testing recommended if available</li>
                    <li>Specimens: First-void urine, vaginal/cervical swabs</li>
                </ul>
                
                <div class="warning-box">
                    <strong>Important:</strong> Macrolide resistance >50% - resistance-guided therapy preferred
                </div>
            </div>
        </div>
        
        <!-- Slide 27: Bacterial Vaginosis -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 27 of 45</p>
                <h1>Bacterial Vaginosis Diagnosis</h1>
            </div>
            <div class="content">
                <h3>Overview</h3>
                <ul>
                    <li>Polymicrobial dysbiosis - not single pathogen</li>
                    <li>Loss of lactobacilli, overgrowth of anaerobes</li>
                    <li>Most common cause of vaginal discharge</li>
                    <li>Associated with STI acquisition, pregnancy complications</li>
                </ul>
                
                <h3>Diagnostic Methods</h3>
                
                <div class="two-column">
                    <div>
                        <h4>Amsel Criteria (3 of 4)</h4>
                        <ul>
                            <li>Thin, homogeneous discharge</li>
                            <li>pH >4.5</li>
                            <li>Positive whiff test</li>
                            <li>Clue cells on microscopy</li>
                        </ul>
                    </div>
                    <div>
                        <h4>Nugent Score (Gram stain)</h4>
                        <ul>
                            <li>0-3: Normal</li>
                            <li>4-6: Intermediate</li>
                            <li>7-10: BV</li>
                            <li>Gold standard method</li>
                        </ul>
                    </div>
                </div>
                
                <h3>NAAT Tests</h3>
                <ul>
                    <li>BD Affirm, BD Max vaginal panel</li>
                    <li>Detect BV-associated bacteria</li>
                    <li>Good correlation with Nugent score</li>
                </ul>
            </div>
        </div>
        
        <!-- Slide 28: Other Pathogens -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 28 of 45</p>
                <h1>Other STI Pathogens</h1>
            </div>
            <div class="content">
                <h3>Chancroid (Haemophilus ducreyi)</h3>
                <ul>
                    <li>Rare in developed countries</li>
                    <li>Clinical diagnosis often sufficient</li>
                    <li>Culture: Special media, <80% sensitive</li>
                    <li>PCR available in research settings</li>
                </ul>
                
                <h3>Candidiasis</h3>
                <ul>
                    <li>Not sexually transmitted but common co-diagnosis</li>
                    <li>Wet mount: Budding yeast, pseudohyphae</li>
                    <li>Culture if recurrent/complicated</li>
                    <li>Species identification for antifungal selection</li>
                </ul>
                
                <h3>Viral Hepatitis</h3>
                <table>
                    <tr>
                        <th>Virus</th>
                        <th>Initial Test</th>
                        <th>Confirmation</th>
                    </tr>
                    <tr>
                        <td>Hepatitis B</td>
                        <td>HBsAg, Anti-HBc</td>
                        <td>HBV DNA if positive</td>
                    </tr>
                    <tr>
                        <td>Hepatitis C</td>
                        <td>Anti-HCV</td>
                        <td>HCV RNA if positive</td>
                    </tr>
                </table>
            </div>
        </div>
        
        <!-- Slide 29: Point-of-Care Testing -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 29 of 45</p>
                <h1>Point-of-Care Testing</h1>
            </div>
            <div class="content">
                <h3>Available POC Tests</h3>
                
                <div class="test-comparison">
                    <div class="test-card">
                        <h4>HIV</h4>
                        <ul>
                            <li>Rapid antibody tests</li>
                            <li>4th gen Ag/Ab tests</li>
                            <li>Results in 20 minutes</li>
                        </ul>
                    </div>
                    <div class="test-card">
                        <h4>Syphilis</h4>
                        <ul>
                            <li>Treponemal tests</li>
                            <li>Dual HIV/syphilis</li>
                            <li>Confirm with lab tests</li>
                        </ul>
                    </div>
                    <div class="test-card">
                        <h4>Trichomonas</h4>
                        <ul>
                            <li>Antigen detection</li>
                            <li>OSOM Trichomonas</li>
                            <li>10-minute results</li>
                        </ul>
                    </div>
                </div>
                
                <h3>Advantages and Limitations</h3>
                <div class="two-column">
                    <div>
                        <h4>Advantages</h4>
                        <ul>
                            <li>Immediate results</li>
                            <li>Same-visit treatment</li>
                            <li>Improved patient flow</li>
                            <li>Outreach settings</li>
                        </ul>
                    </div>
                    <div>
                        <h4>Limitations</h4>
                        <ul>
                            <li>Lower sensitivity</li>
                            <li>Limited test menu</li>
                            <li>Quality control issues</li>
                            <li>Higher cost per test</li>
                        </ul>
                    </div>
                </div>
            </div>
        </div>
        
        <!-- Slide 30: Multiplex Testing -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 30 of 45</p>
                <h1>Multiplex PCR Panels</h1>
            </div>
            <div class="content">
                <h3>Available Multiplex Panels</h3>
                
                <table>
                    <tr>
                        <th>Panel</th>
                        <th>Pathogens Detected</th>
                        <th>Specimen Types</th>
                    </tr>
                    <tr>
                        <td>CT/NG</td>
                        <td>C. trachomatis, N. gonorrhoeae</td>
                        <td>Multiple sites</td>
                    </tr>
                    <tr>
                        <td>Vaginal Panel</td>
                        <td>BV, Candida, Trichomonas</td>
                        <td>Vaginal swab</td>
                    </tr>
                    <tr>
                        <td>Extended STI</td>
                        <td>CT, NG, TV, MG, HSV, Syphilis</td>
                        <td>Genital, urine</td>
                    </tr>
                </table>
                
                <h3>Benefits</h3>
                <ul>
                    <li>Comprehensive testing from single specimen</li>
                    <li>Detects co-infections</li>
                    <li>Efficient workflow</li>
                    <li>Syndrome-based approach</li>
                </ul>
                
                <div class="info-box">
                    <strong>Consideration:</strong> Cost-effectiveness depends on prevalence and testing volume
                </div>
            </div>
        </div>
        
        <!-- Slide 31: Future Technologies -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 31 of 45</p>
                <h1>Future Diagnostic Technologies</h1>
            </div>
            <div class="content">
                <h3>Emerging Technologies</h3>
                
                <div class="test-comparison">
                    <div class="test-card">
                        <h4>Digital PCR</h4>
                        <ul>
                            <li>Absolute quantification</li>
                            <li>Higher precision</li>
                            <li>Resistance detection</li>
                        </ul>
                    </div>
                    <div class="test-card">
                        <h4>NGS</h4>
                        <ul>
                            <li>Microbiome analysis</li>
                            <li>Unknown pathogen ID</li>
                            <li>Resistance genes</li>
                        </ul>
                    </div>
                    <div class="test-card">
                        <h4>AI/Machine Learning</h4>
                        <ul>
                            <li>Result interpretation</li>
                            <li>Risk prediction</li>
                            <li>Quality improvement</li>
                        </ul>
                    </div>
                </div>
                
                <h3>Self-Collection Advances</h3>
                <ul>
                    <li>Home testing kits with app integration</li>
                    <li>Dried blood spots for serology</li>
                    <li>Self-collected vaginal swabs standard of care</li>
                    <li>Mailed specimens with tracking</li>
                </ul>
                
                <div class="success-box">
                    <strong>Future Vision:</strong> Integrated digital health platforms with rapid, accurate home testing
                </div>
            </div>
        </div>
        
        <!-- Slide 32: Saudi Guidelines -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 32 of 45</p>
                <h1>Saudi National Screening Guidelines</h1>
            </div>
            <div class="content">
                <h3>Recommended Screening Protocols</h3>
                
                <table>
                    <tr>
                        <th>Population</th>
                        <th>Tests Recommended</th>
                        <th>Frequency</th>
                    </tr>
                    <tr>
                        <td>Pregnant women</td>
                        <td>Syphilis, HIV, HBV</td>
                        <td>First visit + 3rd trimester</td>
                    </tr>
                    <tr>
                        <td>High-risk adults</td>
                        <td>HIV, Syphilis, CT/NG</td>
                        <td>Annual or more frequent</td>
                    </tr>
                    <tr>
                        <td>STI clinic attendees</td>
                        <td>Comprehensive panel</td>
                        <td>At presentation</td>
                    </tr>
                    <tr>
                        <td>Pre-marital</td>
                        <td>Per national program</td>
                        <td>Once</td>
                    </tr>
                </table>
                
                <h3>Laboratory Network</h3>
                <ul>
                    <li>Reference laboratories for confirmatory testing</li>
                    <li>Regional labs for routine screening</li>
                    <li>Point-of-care in remote areas</li>
                    <li>Quality assurance program mandatory</li>
                </ul>
                
                <div class="info-box">
                    <strong>Integration:</strong> Laboratory results linked to HESN surveillance system
                </div>
            </div>
        </div>
        
        <!-- Slide 33: Quality Assurance Programs -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 33 of 45</p>
                <h1>Quality Assurance Implementation</h1>
            </div>
            <div class="content">
                <h3>Internal Quality Control</h3>
                
                <div class="algorithm-box">
                    <h4>Daily Requirements</h4>
                    <ul>
                        <li>Run positive and negative controls</li>
                        <li>Monitor test performance indicators</li>
                        <li>Document all QC results</li>
                        <li>Investigate out-of-range results</li>
                    </ul>
                </div>
                
                <h3>External Quality Assessment</h3>
                <table>
                    <tr>
                        <th>Program</th>
                        <th>Frequency</th>
                        <th>Requirements</th>
                    </tr>
                    <tr>
                        <td>WHO EQA</td>
                        <td>Bi-annual</td>
                        <td>Syphilis serology</td>
                    </tr>
                    <tr>
                        <td>CAP Surveys</td>
                        <td>Quarterly</td>
                        <td>All STI tests</td>
                    </tr>
                    <tr>
                        <td>National Program</td>
                        <td>Annual</td>
                        <td>Core tests</td>
                    </tr>
                </table>
                
                <h3>Performance Indicators</h3>
                <ul>
                    <li>Test rejection rates <2%</li>
                    <li>TAT within targets</li>
                    <li>EQA scores >80%</li>
                    <li>Critical value reporting 100%</li>
                </ul>
            </div>
        </div>
        
        <!-- Slide 34: Laboratory Communication -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 34 of 45</p>
                <h1>Effective Clinical Communication</h1>
            </div>
            <div class="content">
                <h3>Critical Value Reporting</h3>
                
                <div class="warning-box">
                    <h4>Must Report Immediately:</h4>
                    <ul>
                        <li>Positive syphilis in pregnancy</li>
                        <li>Positive N. gonorrhoeae (any site)</li>
                        <li>New HIV diagnosis</li>
                        <li>Congenital syphilis suspects</li>
                    </ul>
                </div>
                
                <h3>Laboratory Reports Should Include</h3>
                <ul>
                    <li>Clear test name and methodology</li>
                    <li>Reference ranges/interpretive criteria</li>
                    <li>Clinical significance comments</li>
                    <li>Follow-up testing recommendations</li>
                    <li>Contact for questions</li>
                </ul>
                
                <h3>Common Communication Issues</h3>
                <div class="two-column">
                    <div>
                        <h4>Problems</h4>
                        <ul>
                            <li>Unclear test requests</li>
                            <li>Missing clinical info</li>
                            <li>Result misinterpretation</li>
                        </ul>
                    </div>
                    <div>
                        <h4>Solutions</h4>
                        <ul>
                            <li>Standardized order sets</li>
                            <li>Required fields</li>
                            <li>Education programs</li>
                        </ul>
                    </div>
                </div>
            </div>
        </div>
        
        <!-- Slide 35: Case Study 1 -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 35 of 45</p>
                <h1>Case Study 1: Syphilis Diagnosis</h1>
            </div>
            <div class="content">
                <h3>Clinical Scenario</h3>
                <div class="info-box">
                    <p><strong>Patient:</strong> 28-year-old male</p>
                    <p><strong>Presentation:</strong> Painless genital ulcer for 1 week</p>
                    <p><strong>History:</strong> New sexual partner 3 weeks ago</p>
                </div>
                
                <h3>Laboratory Approach</h3>
                <ol>
                    <li><strong>Direct detection:</strong> Swab ulcer for darkfield or PCR</li>
                    <li><strong>Serology:</strong> RPR and TPPA</li>
                    <li><strong>Additional:</strong> HIV, HSV PCR (rule out)</li>
                </ol>
                
                <h3>Results</h3>
                <ul>
                    <li>Darkfield: Positive for spirochetes</li>
                    <li>RPR: Reactive 1:32</li>
                    <li>TPPA: Positive</li>
                    <li>HIV: Negative</li>
                </ul>
                
                <div class="success-box">
                    <strong>Diagnosis:</strong> Primary syphilis<br>
                    <strong>Action:</strong> Treat, partner notification, follow-up serology at 6 & 12 months
                </div>
            </div>
        </div>
        
        <!-- Slide 36: Case Study 2 -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 36 of 45</p>
                <h1>Case Study 2: Persistent Urethritis</h1>
            </div>
            <div class="content">
                <h3>Clinical Scenario</h3>
                <div class="info-box">
                    <p><strong>Patient:</strong> 25-year-old male</p>
                    <p><strong>Presentation:</strong> Persistent urethral discharge after treatment</p>
                    <p><strong>History:</strong> Treated for gonorrhea 3 weeks ago</p>
                </div>
                
                <h3>Initial Testing</h3>
                <ul>
                    <li>CT/NG NAAT: Both negative</li>
                    <li>Gram stain: WBCs, no organisms</li>
                </ul>
                
                <h3>Additional Testing Indicated</h3>
                <ol>
                    <li><strong>M. genitalium NAAT</strong> - Common cause of persistent NGU</li>
                    <li><strong>T. vaginalis NAAT</strong> - Can cause urethritis in men</li>
                    <li><strong>HSV PCR</strong> - If any lesions</li>
                </ol>
                
                <h3>Results & Management</h3>
                <ul>
                    <li>M. genitalium: Positive</li>
                    <li>Resistance testing: Macrolide resistant</li>
                </ul>
                
                <div class="warning-box">
                    <strong>Treatment:</strong> Moxifloxacin-based regimen due to resistance
                </div>
            </div>
        </div>
        
        <!-- Slide 37: Case Study 3 -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 37 of 45</p>
                <h1>Case Study 3: Pregnancy Screening</h1>
            </div>
            <div class="content">
                <h3>Clinical Scenario</h3>
                <div class="info-box">
                    <p><strong>Patient:</strong> 22-year-old pregnant woman</p>
                    <p><strong>Presentation:</strong> First prenatal visit at 12 weeks</p>
                    <p><strong>History:</strong> No STI symptoms</p>
                </div>
                
                <h3>Recommended Testing</h3>
                <table>
                    <tr>
                        <th>Test</th>
                        <th>Result</th>
                        <th>Action</th>
                    </tr>
                    <tr>
                        <td>Syphilis (RPR)</td>
                        <td>Reactive 1:4</td>
                        <td>Confirm with TPPA</td>
                    </tr>
                    <tr>
                        <td>TPPA</td>
                        <td>Positive</td>
                        <td>Stage & treat urgently</td>
                    </tr>
                    <tr>
                        <td>HIV</td>
                        <td>Negative</td>
                        <td>Repeat 3rd trimester</td>
                    </tr>
                    <tr>
                        <td>HBsAg</td>
                        <td>Negative</td>
                        <td>Routine follow-up</td>
                    </tr>
                    <tr>
                        <td>CT/NG</td>
                        <td>CT positive</td>
                        <td>Treat & test of cure</td>
                    </tr>
                </table>
                
                <div class="warning-box">
                    <strong>Critical:</strong> Untreated syphilis → 40% risk of congenital syphilis
                </div>
            </div>
        </div>
        
        <!-- Slide 38: Troubleshooting -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 38 of 45</p>
                <h1>Laboratory Troubleshooting</h1>
            </div>
            <div class="content">
                <h3>Common Issues and Solutions</h3>
                
                <table>
                    <tr>
                        <th>Problem</th>
                        <th>Possible Causes</th>
                        <th>Solutions</th>
                    </tr>
                    <tr>
                        <td>NAAT inhibition</td>
                        <td>Blood, mucus, preservatives</td>
                        <td>Dilute specimen, use different platform</td>
                    </tr>
                    <tr>
                        <td>Culture contamination</td>
                        <td>Poor technique, transport delay</td>
                        <td>Training, selective media, rapid transport</td>
                    </tr>
                    <tr>
                        <td>Discordant serology</td>
                        <td>Early infection, false positive</td>
                        <td>Repeat testing, alternative methods</td>
                    </tr>
                    <tr>
                        <td>Invalid controls</td>
                        <td>Storage, expiration, technique</td>
                        <td>Check storage, new lot, retrain staff</td>
                    </tr>
                </table>
                
                <h3>When to Reject Specimens</h3>
                <ul>
                    <li>Unlabeled or mislabeled</li>
                    <li>Wrong transport medium</li>
                    <li>Excessive transport time</li>
                    <li>Visible contamination</li>
                    <li>Insufficient quantity</li>
                </ul>
                
                <div class="info-box">
                    <strong>Best Practice:</strong> Communicate with clinical team before rejecting irreplaceable specimens
                </div>
            </div>
        </div>
        
        <!-- Slide 39: Surveillance Integration -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 39 of 45</p>
                <h1>Public Health Surveillance Integration</h1>
            </div>
            <div class="content">
                <h3>Reportable STIs in Saudi Arabia</h3>
                <ul>
                    <li>Syphilis - All stages</li>
                    <li>Gonorrhea - All sites</li>
                    <li>Chlamydia - All sites</li>
                    <li>HIV - New diagnoses</li>
                    <li>Congenital infections</li>
                </ul>
                
                <h3>Laboratory's Role in Surveillance</h3>
                <ol>
                    <li><strong>Timely reporting:</strong> Within 24-48 hours</li>
                    <li><strong>Complete data:</strong> Demographics, test results, specimen source</li>
                    <li><strong>Quality data:</strong> Accurate test coding, avoid duplicates</li>
                    <li><strong>Resistance data:</strong> Antimicrobial susceptibility results</li>
                </ol>
                
                <h3>HESN Plus Integration</h3>
                <div class="algorithm-box">
                    <ul>
                        <li>Electronic reporting preferred</li>
                        <li>Standardized case definitions</li>
                        <li>Link laboratory and clinical data</li>
                        <li>Support outbreak investigations</li>
                    </ul>
                </div>
            </div>
        </div>
        
        <!-- Slide 40: Cost Considerations -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 40 of 45</p>
                <h1>Cost-Effective Testing Strategies</h1>
            </div>
            <div class="content">
                <h3>Optimizing Test Utilization</h3>
                
                <div class="two-column">
                    <div>
                        <h4>Avoid Overuse</h4>
                        <ul>
                            <li>HSV serology screening</li>
                            <li>Repeat treponemal tests</li>
                            <li>Culture when NAAT available</li>
                            <li>Too frequent retesting</li>
                        </ul>
                    </div>
                    <div>
                        <h4>Don't Miss</h4>
                        <ul>
                            <li>Extragenital testing</li>
                            <li>Syphilis in pregnancy</li>
                            <li>Resistance testing</li>
                            <li>Partner testing</li>
                        </ul>
                    </div>
                </div>
                
                <h3>Cost-Effectiveness Strategies</h3>
                <ul>
                    <li><strong>Pooled testing:</strong> For low-prevalence screening</li>
                    <li><strong>Reflex testing:</strong> Automatic confirmatory tests</li>
                    <li><strong>Syndromic panels:</strong> When multiple pathogens likely</li>
                    <li><strong>Risk-based screening:</strong> Target high-risk populations</li>
                </ul>
                
                <div class="success-box">
                    <strong>Remember:</strong> Preventing one case of PID or congenital syphilis saves more than hundreds of tests cost
                </div>
            </div>
        </div>
        
        <!-- Slide 41: Key Messages -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 41 of 45</p>
                <h1>Key Laboratory Messages</h1>
            </div>
            <div class="content">
                <h3>Critical Points to Remember</h3>
                
                <div class="algorithm-box">
                    <ol>
                        <li><strong>NAAT is preferred</strong> for CT, NG, TV, MG when available</li>
                        <li><strong>Syphilis requires two tests</strong> - treponemal + non-treponemal</li>
                        <li><strong>Culture is essential</strong> for antimicrobial resistance monitoring</li>
                        <li><strong>Specimen quality</strong> determines test performance</li>
                        <li><strong>Extragenital testing</strong> based on sexual practices</li>
                    </ol>
                </div>
                
                <h3>Common Pitfalls to Avoid</h3>
                <ul>
                    <li>Using treponemal tests to monitor syphilis treatment</li>
                    <li>Testing too soon after exposure (window period)</li>
                    <li>Ignoring pre-analytical requirements</li>
                    <li>Not confirming positive screening tests</li>
                    <li>Poor communication with clinicians</li>
                </ul>
                
                <div class="info-box">
                    <strong>Excellence in STI testing requires continuous education and quality improvement</strong>
                </div>
            </div>
        </div>
        
        <!-- Slide 42: Future Directions -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 42 of 45</p>
                <h1>Future of STI Diagnostics in Saudi Arabia</h1>
            </div>
            <div class="content">
                <h3>National Laboratory Priorities</h3>
                <ul>
                    <li>Expand molecular testing capacity</li>
                    <li>Implement resistance surveillance</li>
                    <li>Strengthen point-of-care networks</li>
                    <li>Integrate with digital health systems</li>
                    <li>Develop local validation studies</li>
                </ul>
                
                <h3>Vision 2030 Alignment</h3>
                <div class="two-column">
                    <div>
                        <h4>Technology</h4>
                        <ul>
                            <li>AI-assisted diagnostics</li>
                            <li>Automated platforms</li>
                            <li>Home testing options</li>
                            <li>Real-time surveillance</li>
                        </ul>
                    </div>
                    <div>
                        <h4>Access</h4>
                        <ul>
                            <li>Equitable test availability</li>
                            <li>Reduced turnaround times</li>
                            <li>Cost-effective strategies</li>
                            <li>Quality standardization</li>
                        </ul>
                    </div>
                </div>
                
                <div class="success-box">
                    <strong>Goal:</strong> Achieve STI elimination targets through excellence in laboratory diagnostics
                </div>
            </div>
        </div>
        
        <!-- Slide 43: Resources -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 43 of 45</p>
                <h1>Resources and References</h1>
            </div>
            <div class="content">
                <h3>Key Guidelines</h3>
                <ul>
                    <li>Saudi MOH STI Treatment Guidelines 2024</li>
                    <li>WHO Laboratory Manual for STI Diagnosis</li>
                    <li>CDC STI Treatment Guidelines 2021</li>
                    <li>BASHH UK Testing Guidelines</li>
                </ul>
                
                <h3>Professional Organizations</h3>
                <ul>
                    <li>Saudi Society for Clinical Microbiology</li>
                    <li>International Union against STIs (IUSTI)</li>
                    <li>American Society for Microbiology (ASM)</li>
                </ul>
                
                <h3>Continuing Education</h3>
                <ul>
                    <li>Annual Saudi STI symposium</li>
                    <li>WHO online training modules</li>
                    <li>International proficiency programs</li>
                    <li>Manufacturer training programs</li>
                </ul>
                
                <div class="info-box">
                    <strong>Stay Updated:</strong> Subscribe to STI laboratory networks and journals
                </div>
            </div>
        </div>
        
        <!-- Slide 44: Summary -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 44 of 45</p>
                <h1>Summary</h1>
            </div>
            <div class="content">
                <h3>Laboratory Diagnosis is Critical for STI Control</h3>
                
                <div class="algorithm-box">
                    <h4>Key Takeaways</h4>
                    <ol>
                        <li>Accurate diagnosis guides appropriate treatment</li>
                        <li>Different pathogens require different approaches</li>
                        <li>Quality at every step - pre-analytical to post-analytical</li>
                        <li>NAAT has revolutionized STI testing</li>
                        <li>Resistance surveillance is increasingly important</li>
                        <li>Integration with public health is essential</li>
                    </ol>
                </div>
                
                <h3>Call to Action</h3>
                <ul>
                    <li>Implement best practices in your laboratory</li>
                    <li>Participate in quality assurance programs</li>
                    <li>Collaborate with clinical teams</li>
                    <li>Support surveillance efforts</li>
                    <li>Continue professional development</li>
                </ul>
                
                <div class="success-box" style="margin-top: 30px; text-align: center; font-size: 20px;">
                    <strong>Together, we can achieve STI control through laboratory excellence</strong>
                </div>
            </div>
        </div>
        
        <!-- Slide 45: Thank You -->
        <div class="slide">
            <div class="slide-header">
                <p class="slide-number">Slide 45 of 45</p>
                <h1>Thank You</h1>
            </div>
            <div class="content" style="text-align: center; padding-top: 100px;">
                <h2>Questions and Discussion</h2>
                
                <div style="margin-top: 60px;">
                    <p style="font-size: 24px; color: #475569;">Thank you for your attention and participation</p>
                    <p style="font-size: 20px; color: #64748b; margin-top: 20px;">Together for a healthier Saudi Arabia</p>
                </div>
                
                <div style="margin-top: 80px;">
                    <p style="font-size: 18px; color: #94a3b8;">Ministry of Health<br>STI Control Program<br>Laboratory Excellence Initiative</p>
                </div>
            </div>
        </div>
        
        <div class="navigation">
            <button class="nav-button" id="prevBtn" onclick="changeSlide(-1)">Previous</button>
            <span class="slide-indicator" id="slideIndicator">1 / 45</span>
            <button class="nav-button" id="nextBtn" onclick="changeSlide(1)">Next</button>
        </div>
    </div>
    
    <script>
        let currentSlide = 0;
        const slides = document.querySelectorAll('.slide');
        const totalSlides = slides.length;
        
        // Set current date
        document.getElementById('currentDate').textContent = new Date().toLocaleDateString('en-US', { 
            year: 'numeric', 
            month: 'long', 
            day: 'numeric' 
        });
        
        function showSlide(n) {
            slides.forEach(slide => slide.classList.remove('active'));
            
            currentSlide = (n + totalSlides) % totalSlides;
            slides[currentSlide].classList.add('active');
            
            document.getElementById('slideIndicator').textContent = `${currentSlide + 1} / ${totalSlides}`;
            
            // Update navigation buttons
            document.getElementById('prevBtn').disabled = currentSlide === 0;
            document.getElementById('nextBtn').disabled = currentSlide === totalSlides - 1;
            
            // Update progress bar
            const progress = ((currentSlide + 1) / totalSlides) * 100;
            document.getElementById('progressBar').style.width = `${progress}%`;
        }
        
        function changeSlide(direction) {
            showSlide(currentSlide + direction);
        }
        
        // Keyboard navigation
        document.addEventListener('keydown', (e) => {
            if (e.key === 'ArrowRight' && currentSlide < totalSlides - 1) {
                changeSlide(1);
            } else if (e.key === 'ArrowLeft' && currentSlide > 0) {
                changeSlide(-1);
            } else if (e.key === 'Home') {
                showSlide(0);
            } else if (e.key === 'End') {
                showSlide(totalSlides - 1);
            }
        });
        
        // Initialize
        showSlide(0);
        
        // Add slide numbers to title for easier reference during presentation
        slides.forEach((slide, index) => {
            if (index > 0) { // Skip title slide
                const slideNum = slide.querySelector('.slide-number');
                if (slideNum) {
                    slideNum.style.cursor = 'pointer';
                    slideNum.onclick = () => {
                        const goTo = prompt(`Go to slide (1-${totalSlides}):`);
                        if (goTo && !isNaN(goTo)) {
                            const slideIndex = parseInt(goTo) - 1;
                            if (slideIndex >= 0 && slideIndex < totalSlides) {
                                showSlide(slideIndex);
                            }
                        }
                    };
                }
            }
        });
    </script>
</body>

</html>

